This podcast episode explores the critical role community oncology plays in the U.S. healthcare system and why supporting its growth and autonomy matters for patients and providers.

Original title: “[Podcast] Closing the Distance in Cancer Care”

Of the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb. The remaining five assets will be jointly discovered.

Original title: “BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal”

Second national grant strengthens company’s expanding global IP estate

Original title: “Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS”

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is actively seeking potential licensees interested in further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases.

Original title: “Government Owned Inventions Available for License: Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1”

Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.

Original title: “Lilly, Gilead lead pharma’s M&A boom”

Roche plans to offer PathAI’s tools as part of an effort to improve cancer diagnosis and tailored treatment.

Original title: “Roche to acquire digital pathology firm PathAI in deal potentially worth over $1B”

Partnership builds on existing collaboration and adds two new UCB‑nominated projects

Original title: “UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies”

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the Supplementary Information section of this notice to OncoVanta Therapeutics, Inc. ("OncoVanta"), a company located in Hagerstown, Maryland, the United States of America.

Original title: “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of Cancer”

pathodashboard an epidemiological atlas for tumour diagnostics german version

Original title: “[Pathodashboard: an epidemiological atlas for tumour diagnostics. German version].”

best practice recommendations for bioinformatics approaches applied to high throughput sequencing for rare disease and cancer diagnosis within the uk national health service

Original title: “Best practice recommendations for bioinformatics approaches applied to high-throughput sequencing for rare disease and cancer diagnosis within the UK National Health Service.”

clinical landscape of hif2 inhibitors in oncology

Original title: “The clinical landscape of HIF2α inhibitors in oncology.”

crosstalk between epigenetics and metabolism in the malignant cell

Original title: “The crosstalk between epigenetics and metabolism in the malignant cell.”

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or efficacy concerns.

Original title: “Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer”

high index facet distorted lanthanum cuprate for ultrasound triggered cuproptosis and cascade amplified antitumor therapy

Original title: “High-Index Facet-Distorted Lanthanum Cuprate for Ultrasound-Triggered Cuproptosis and Cascade-Amplified Antitumor Therapy.”

assessing the contribution of rare dna states to cancer mutational signatures using sequence specific conformational fingerprinting

Original title: “Assessing the contribution of rare DNA states to cancer mutational signatures using sequence-specific conformational fingerprinting.”

host guest interaction instructed in situ self assembly of therapeutic peptides for enhancing antitumor efficacy

Original title: “Host-Guest Interaction-Instructed In Situ Self-Assembly of Therapeutic Peptides for Enhancing Antitumor Efficacy.”

mechanically triggered dna nanovehicles for targeted dual drug cancer therapy

Original title: “Mechanically Triggered DNA Nanovehicles for Targeted Dual-Drug Cancer Therapy.”

Eli Lilly is putting its obesity windfall to work again, striking a new deal to acquire CrossBridge Bio, a small Texas biotech known for its cancer tech.

Original title: “Lilly wants to bridge cancer care gap with $300M ADC biotech buy”

Smaller gene-editing system could expand treatment options for cancer, ALS and other diseases.

Original title: “NIH-funded breakthrough shrinks CRISPR for precision delivery in the body”

Telix is Regeneron’s entry ticket into the radiopharma game, helping to better round out the company's cancer portfolio, according to Truist Securities.

Original title: “Regeneron enters radiopharma ring with up to $4.3B Telix alliance”